Literature DB >> 18544578

Why do couples drop-out from IVF treatment? A prospective cohort study.

M F G Verberg1, M J C Eijkemans, E M E W Heijnen, F J Broekmans, C de Klerk, B C J M Fauser, N S Macklon.   

Abstract

BACKGROUND: Cumulative IVF pregnancy rates are compromised by the large number of couples who drop-out of treatment before achieving pregnancy. The aim of this study was to identify the role of the treatment strategy applied, and potential other factors that influence the decision of couples to discontinue treatment.
METHODS: The incidence of drop-out from IVF treatment and factors related to drop-out were studied in a cohort of IVF patients aged <38 years embarking on IVF treatment either with a mild or a standard treatment strategy for a planned maximum number of treatment cycles.
RESULTS: Of the 384 couples studied, 17% dropped out of IVF treatment. The physical or psychological burden of treatment was the most frequent cause of drop-out (28%). The application of a mild treatment strategy (mild ovarian stimulation along with the transfer of a single embryo) significantly reduced the chance of drop-out (hazard ratio (HR) 0.55; 95% confidence interval (CI), 0.31-0.96). When a mild IVF strategy was employed, the association between the baseline anxiety score and drop-out was reduced by >50%. The presence of severe male subfertility (HR 4.80; 95% CI, 1.63-14.13) and the failure to achieve embryo transfer (odds ratio 0.41; 95% CI, 0.24-0.72) were also related to drop-out.
CONCLUSIONS: Reducing drop-out rate is crucial to further improve the efficacy and cost-effectiveness of IVF treatment. An important factor determining the risk of drop-out is the burden of the treatment strategy. The application of a mild treatment strategy and managing patient's expectations might reduce drop-out rates.

Entities:  

Mesh:

Year:  2008        PMID: 18544578     DOI: 10.1093/humrep/den219

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  52 in total

1.  Predictors of not pursuing infertility treatment after an infertility diagnosis: examination of a prospective U.S. cohort.

Authors:  Michael L Eisenberg; James F Smith; Susan G Millstein; Robert D Nachtigall; Nancy E Adler; Lauri A Pasch; Patricia P Katz
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

2.  Double trouble: should double embryo transfer be banned?

Authors:  Dominic Wilkinson; G Owen Schaefer; Kelton Tremellen; Julian Savulescu
Journal:  Theor Med Bioeth       Date:  2015-04

3.  ISMAAR: Leading the global agenda for a more physiological, patient-centred, accessible and safer approaches in ART.

Authors:  Geeta Nargund; R C Chian
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

4.  Precycle Estradiol in Synchronization and Scheduling of Antagonist Cycles.

Authors:  Shilpa Saple; Mukesh Agrawal; Simi Kawar
Journal:  J Obstet Gynaecol India       Date:  2016-04-29

5.  The impact of younger age on treatment discontinuation in insured IVF patients.

Authors:  Laura E Dodge; Denny Sakkas; Michele R Hacker; Rachael Feuerstein; Alice D Domar
Journal:  J Assist Reprod Genet       Date:  2016-11-26       Impact factor: 3.412

6.  Mild ovarian stimulation for in vitro fertilization: one perspective from the USA.

Authors:  Valerie L Baker
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

7.  Time costs of fertility care: the hidden hardship of building a family.

Authors:  Alex K Wu; Peter Elliott; Patricia P Katz; James F Smith
Journal:  Fertil Steril       Date:  2013-02-28       Impact factor: 7.329

8.  Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study.

Authors:  J Thomas Welcker; Frank Nawroth; Wilma Bilger
Journal:  Reprod Biol Endocrinol       Date:  2010-09-15       Impact factor: 5.211

9.  A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle.

Authors:  Bülent Haydardedeoğlu; Esra Bulgan Kılıçdağ
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-09-01

10.  A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.

Authors:  P Devroey; R Boostanfar; N P Koper; B M J L Mannaerts; P C Ijzerman-Boon; B C J M Fauser
Journal:  Hum Reprod       Date:  2009-08-14       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.